Myriad Genetics (MYGN) Current Assets (2010 - 2026)

Myriad Genetics (MYGN) has reported Current Assets for 17 consecutive years, with $312.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 8.91% year-over-year to $312.8 million; the TTM figure through Mar 2026 stood at $312.8 million (up 8.91% YoY), while the FY2025 annual figure was $332.6 million, up 11.61% from the prior year.
• Current Assets retreated to $312.8 million in Q1 2026 per MYGN's latest filing, from $332.6 million in the prior quarter.
• Across five years, Current Assets topped out at $427.4 million in Q1 2022 and bottomed at $261.6 million in Q1 2023.
• Historically, Current Assets has averaged $311.2 million across 5 years, with a median of $294.3 million in 2023.
• On a YoY basis, Current Assets climbed as much as 29.83% in 2022 and fell as far as 43.36% in 2022.
• Myriad Genetics' Current Assets stood at $274.6 million in 2022, then increased by 14.2% to $313.6 million in 2023, then slipped by 4.97% to $298.0 million in 2024, then gained by 11.61% to $332.6 million in 2025, then declined by 5.95% to $312.8 million in 2026.
• Business Quant data shows MYGN's Current Assets at $312.8 million in Q1 2026, $332.6 million in Q4 2025, and $344.8 million in Q3 2025.